

# RARE TUMORS WORKING GROUP



CHICAGO, MAY 2013  
ISABELLE RAY COQUARD & JONATHAN LEDERMANN

# AGENDA



- **Call to Order and Welcome**
- **Review of Minutes of Leiden MEETING 2012**
- **Update on GCIG Rare Tumor Initiative (I Ray-Coquard & J Ledermann)**
- **Update of rare gynecologic cancer GCIG meeting London Nov 2013 (I Ray-Coquard & J Ledermann)**
- **New projects**
- **Other Business**
- **Adjournment**

# SUMMARY



Ov & Ut carcinosarcoma  
low malignant potential tumors  
low grade serous carcinoma  
Sex cord tumor  
germ Cell Tumor  
squamous Ov carcinoma  
Small Cell carcinoma cervix  
small cell carcinoma OV  
vulvar & vagina non squamous carcinoma  
ovarian carcinoid tumor  
pseudomixoma peritonei & mucinous carcinoma  
clear cell carcinoma Ovary  
clear cell carcinoma Cervix & Ut  
trophoblastic diseases  
low grade endometrial stromal sarcoma  
HG uterine sarcoma  
uterine papillary serous carcinoma  
adenosarcoma  
Ut & Ov leiomyosarcoma  
glandular carcinoma of cervix

## **20 DOCUMENTS:**

**18 sent at least a first draft  
(MEoc, BL waiting)**

**4 completely finalized**

**4 2<sup>nd</sup> draft waiting**

**7 under validation by group/chairs**

**3 under review by co coordinator**

# Questions & discussions



- **Definition of the project :**
  - GCIG rare tumor consensus review
- **Relation with other groups/societies:**
  - WSN, ISSTD, EOSTD, .....
- **Next steps for publication:**
  - Review by national groups will be done on Sept
  - Finalization by an “editing board” I R-C, JAL, M. Friedlander, K Lorusso, E Kohn, D Gershenson, A Oza for October
  - Final version posted on GCIG website
- **Next meeting specifically dedicated to review documents ESMO meeting (Amsterdam 2013)**

# GCIIG Rare Tumors Planning Meeting – London, 16 Nov 2013

**Participants:** GCIIG groups (2-3 representatives for each group) & invited speakers / experts in the field

## **Objectives:**

- To define current guidelines for rare gynecologic tumors;
- To define control arm for present and future clinical trials involving rare cancer;
- To identify national & international barriers for trials dedicated to rare gynecologic cancers
- To summarize and prioritize key issues for research and agree new set of trial concepts to address the key issues in several rare tumors
- To prioritize and design 3 international initiatives in rare gynecologic cancer

# GCIG Rare Tumors Planning Meeting – London, 16 Nov 2013

- Welcome, objectives
- Review & validation of the GCIG rare cancers documents
- Main statistical issues for ongoing & future trials
- Main harmonization/Regulation issues
- Complexities of collecting samples across international boundaries -
- Example of successful story from other cancers/groups
- II part : 3 working groups sessions
  - 1) relatively rare tumors
  - 2) rare tumors
  - 3) very rare tumors

# GCIIG on –going trials or potential trials



- **Alienor (GINECO)**
- **GOG0275 (UC1005): A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia. J Schink**